Docetaxel and epirubicin plus G-CSF mobilize hematopoietic progenitors in breast cancer [4]

Annals of Oncology

Volumn 10, Issue 12, 1999, Pages 1531-1532

  Pierelli, L ^a   Leone, G ^a   Cortesi, E ^a   Martelli, O ^a   Perillo, A ^b   Mancuso, S ^b   Scambia, G ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; DRUG EFFICACY; HEMATOPOIETIC STEM CELL; LETTER; LEUKAPHERESIS; PRIORITY JOURNAL; TREATMENT PLANNING;

EID: 0033398011     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008362120909     Document Type: Letter

References (7)

1. Menichella G, Pierelli L, Scambia G et al. Low-dose cyclophosphamide in combination with cisplatin or epirubicin plus rhG-CSF allows adequate collection of PBSC for autotransplantation during adjuvant therapy for high-risk cancer. Bone Marrow Transplant 1994; 14: 907-12.
2. Venturini M, Del Mastro L, Melioli G et al. Release of peripheral blood progenitor cells during standard dose cyclophosphamide, epidoxorubicin, 5-fluorouracil regimen plus granulocyte colony stimulating factor for breast cancer therapy. Cancer 1994; 74: 2300-6.
3. P. Fumoleau, B. Chevallier, P. Kerbrat et al. A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: Report of the clinical screening group of the EORTC. Ann Oncol 1996; 7 (2): 165-71.
4. Valero V, Jones SE, Von Hoff DD et al. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 1998; 16: 3362-8.
5. Pagani O, Sessa C, Martinelli G et al. Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer. Ann Oncol 1999; 10 (5): 539-45.
6. Benedetti Panici P, Pierelli L, Scambia G et al. High-dose carboplatin, etoposide and melphalan (CEM) with peripheral blood progenitor cell support as late intensification for high-risk cancer: Non-haematological, haematological toxicities and role of growth factor administration. Br J Cancer 1997; 75: 1205-12.
7. Pierelli L, Perillo A, Greggi S et al. Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: Results of a randomized comparison. J Clin Oncol 1999; 17: 1288-95.